I-Mab Logo
  • Investors
  • Careers
  • Contact
  • 简体中文
  • About
    • Story
    • Leadership
    • Responsibility
  • Innovation
    • Science
    • Capability
    • Publications
  • Products
    • Product Pipeline
    • Clinical Trials
  • Partnerships
  • News & Events
    • News
    • Events
I-Mab Logo
  • About
    • Story
    • Leadership
    • Responsibility
  • Innovation
    • Science
    • Capability
    • Publications
  • Products
    • Product Pipeline
    • Clinical Trials
  • Partnerships
  • News & Events
    • News
    • Events
  • Investors
  • Careers
  • Contact
  • 简体中文

Publications & Presentations

  • Lemzoparlimab (TJC4)
  • Uliledlimab (TJD5)
  • Enoblituzumab (TJ271)
  • Efineptakin alfa (TJ107)
  • TJ-CD4B
  • TJ-C64B
  • TJ-C4GM
  • TJ-L1I7

Lemzoparlimab (TJC4)

Lemzoparlimab, a Differentiated Anti-CD47 Antibody in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin’s Lymphoma: Initial Clinical Results

Poster presentation at the 2021 ASH meeting

A first-in-patient study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results

Poster presentation at the 2020 SITC Meeting

TJC4, A Differentiated RBC Sparing Anti-CD47 Antibody for Anti-Cancer Therapy

Poster presentation at the 2019 ASH meeting

A differentiated CD47 therapeutic antibody recognizing a novel epitope and sparing erythrocytes and platelets

Poster presentation at the 2017 EACR meeting

Uliledlimab (TJD5)

The safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab, a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer

Poster presentation at the 2021 ASCO meeting

Enoblituzumab (TJ271)

Inhibition of B7-H3 by Enoblituzumab Elicits Antitumor Immune Modulation in Both Innate and Adaptive Immunity

Poster presentation at the 2022 AACR meeting

Efineptakin alfa (TJ107)

A Phase I/IIa, Open-label, Dose-Escalation and Dose Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients with Advanced Solid Tumors

Poster presentation at the 2019 SITC meeting

TJ-CD4B

TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumor-dependent immune response without dose-limiting toxicity in preclinical studies

Poster presentation at the 2021 SITC meeting

Claudin 18.2 – 4-1BB bispecific antibody induced potent tumor inhibition through tumor-specific 4-1BB activation

Poster presentation at the 2020 AACR meeting

TJ-C64B

Discovery of a novel Claudin6-4-1BB bispecific antibody with potent anti-tumor activity through conditional 4-1BB activation

Poster presentation at the 2022 AACR meeting

TJ-C4GM

A novel immunocytokine fusion protein combining tumor-targeting anti-CD47 antibody with GM-CSF cytokine for enhanced anti-tumor efficacy

Poster presentation at the 2018 AACR meeting

TJ-L1I7

A novel anti-tumor anti-PDL1-IL7 immunocytokine targeting lymphocytes

Poster presentation at the 2019 SITC meeting

Sitemap

  • Home
  • About
  • Innovation
  • Products
  • Partnerships
  • News
  • Investors
  • Careers
  • Contact
  • 简体中文

Follow Us

  • LinkedIn
  • Twitter

Copyright © 2022 I-MAB Biopharma Co., Ltd. All Rights Reserved.

沪ICP备17007960号-2 | 沪公网安备31011502018701号